Sanofi India is planning to lower the price of Rifapentine, a critically important drug used to prevent tuberculosis (TB), as part of the agreement with Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria.
The volume-based agreement will discount the price of a three-month treatment course of Rifapentine by nearly 70 percent, from approximately $45 to $15 (ex works) in the public sectors of 100 low and middle-income countries burdened by TB and TB/HIV coinfection. Scale-up of affordable Rifapentine stands to benefit over a million people in India alone, where more people suffer from TB than anywhere else in the world. The Indian government has set ambitious targets to eliminate TB by 2025.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: